SciClone no longer on the block

SciClone Pharmaceuticals Inc. (NASDAQ:SCLN) fell $2.76 (21%) to $10.50 after it said it is no longer seeking acquirers and plans to remain an independent, publicly traded company. In February, the company said it hired Lazard to seek strategic deals (see BioCentury Extra, Feb. 5). ...